ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2017
The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis.
Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; A systematic review and meta-analysis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Pooled it
- Strict carbohydrate restriction enables volume-based FDG-PET/CT to outperform SUVmax for risk stratification in cardiac sarcoidosis.International journal of cardiology. Heart & vasculature · 2026Article
- Article
- Cardiac sarcoidosis treated with nonsteroidal immunosuppressive therapy.International journal of cardiology. Heart & vasculature · 2024Article
- Current uses and understanding of PET imaging in cardiac sarcoidosis.American journal of nuclear medicine and molecular imaging · 2024Review
- Use of PET/CT to detect myocardial inflammation and the risk of malignant arrhythmia in chronic Chagas disease.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Cardiac magnetic resonance biomarkers as surrogate endpoints in cardiovascular trials for myocardial diseases.European heart journal · 2023Review
- Prednisone vs methotrexate in treatment naïve cardiac sarcoidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Linking cardiac and extracardiac sarcoidosis and their clinical outcome:Annals of nuclear medicine · 2023Article
- FDG uptake patterns in isolated and systemic cardiac sarcoidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- The utility of beta-hydroxybutyrate in detecting myocardial glucose uptake suppression in patients undergoing inflammatory [18F]-FDG PET studies.European journal of nuclear medicine and molecular imaging · 2023Article
- Cardiac sarcoidosis: the role of cardiac MRI andThe British journal of cardiology · 2023Article
- Investigating the treatment phenotypes of cardiac sarcoidosis: A prospective cohort study.American heart journal plus : cardiology research and practice · 2022Article
- The Role of Multimodality Imaging in Cardiac Sarcoidosis.Korean circulation journal · 2021Review
- Activation of cardiac sarcoidosis associated with development of gastric cancer: a case report.European heart journal. Case reports · 2021Article
- Clinical and Imaging Response to Tumor Necrosis Factor Alpha Inhibitors in Treatment of Cardiac Sarcoidosis: A Multicenter Experience.Journal of cardiac failure · 2021Article
- Assessing severity of cardiac sarcoid: Is SUV the answer?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Article
- Management of Cardiac Sarcoidosis in 2020.Arrhythmia & electrophysiology review · 2020Review
- The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study was to determine the feasibility of serial quantitative 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET) to monitor the response of cardiac sarcoidosis to treatment. METHODS AND
resultsA total of 38 PET scan intervals (54 PET scans) were obtained in 16 patients with cardiac sarcoidosis who underwent serial FDG PET during treatment. FDG-avid lesions of the heart were interpreted quantitatively using 4 PET parameters: maximum standardized uptake value (SUVmax), partial volume corrected mean standardized uptake value (SUVmean), partial volume corrected metabolic volume product (MVP), and global metabolic volume product (gMVP). Clinical response to treatment (improved, stable, or progressive disease) was evaluated by clinical symptoms, NYHA class, and EKG in all the patients. SUVmax, SUVmean, MVP, and gMVP had significantly decreased value on repeat PET in patients who were either stable or showed clinical improvement between two serial PET scans, while none of them had significant change on repeat PET in patients who were clinically worse. Correlation analysis between PET findings and clinical assessment revealed that the changes of SUVmax and SUVmean on repeat PET were negatively correlated with patient's clinical outcome.
conclusionOur results indicated that serial FDG PET is feasible to determine the extent of disease activity and to quantitatively assess the response of cardiac sarcoidosis to therapy.
Indexed as
Identifiers
27813028What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.